H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BioCryst (NASDAQ: BCRX) today and set a price target of $10. The company’s shares closed yesterday at $5.03.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.8% and a 49.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
Based on BioCryst’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $19.54 million. In comparison, last year the company had a GAAP net loss of $14.22 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCRX in relation to earlier this year. Most recently, in March 2018, Alane Barnes, the VP, GC & Corp Sec of BCRX bought 6,709 shares for a total of $21,871.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.
